Table 3.

Prediction results in pyrosequencing data

Non-neoplastic tissueNeoplastic tissueStool
Panel markersHealthy controls (n = 39)Sporadic CRC (n = 32)Fisher's PIBD - CRC (n = 27)Fisher's PSporadic CRC (n = 62)Fisher's PIBD - CRC (n = 20)Fisher's PSporadic CRC (n = 87)Fisher's P
AGTR1
 Methylated, n (%)2/39 (5%)0/15 (0%)13/9 (33%)0.039335/54 (65%)2E-094/8 (50%)0.005014/68 (21%)0.0463
 Unmethylated, n (%)37/39 (95%)15/15 (100%)6/9 (67%)19/54 (35%)4/8 (50%)54/68 (79%)
WNT2
 Methylated, n (%)1/39 (3%)3/25 (12%)0.29058/24 (33%)0.001346/56 (82%)5E-1611/19 (58%)3E-0621/52 (40%)1E-05
 Unmethylated, n (%)38/39 (97%)22/25 (88%)16/24 (67%)10/56 (18%)8/19 (42%)31/52 (60%)
SLIT2
 Methylated, n (%)2/37 (5%)1/17 (6%)17/15 (47%)0.001248/56 (86%)2E-156/7 (86%)3E-0537/71 (52%)5E-07
 Unmethylated, n (%)35/37 (95%)16/17 (94%)8/15 (53%)8/56 (14%)1/7 (14%)34/71 (48%)
≥1 methylated gene
 Yes4/38 (11%)4/18 (22%)0.254414/17 (82%)4E-0757/60 (95%)< 2.2E-1613/14 (93%)5E-0850/64 (78%)2E-11
 No34/38 (89%)14/18 (78%)3/17 (18%)3/60 (5%)1/14 (7%)14/64 (22%)
Reference markersHealthy controls (n = 26)Sporadic CRC (n = 14)Fisher's PSporadic CRC (n = 35)Fisher's P
VIM
 Methylated, n (%)3/22 (14%)10/12 (83%)0.000118/33 (55%)0.0040
 Unmethylated, n (%)19/22 (86%)2/12 (17%)15/33 (45%)
SEPT9
 Methylated, n (%)0/26 (0%)13/14 (93%)1E-097/35 (20%)0.0169
 Unmethylated, n (%)26/26 (100%)1/14 (7%)28/35 (80%)

NOTE: Performance of individual genes and the 3-gene panel using methylation estimates from pyrosequencying data.